Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04826224
Other study ID # 20-007731
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 6, 2021
Est. completion date October 2024

Study information

Verified date April 2024
Source Mayo Clinic
Contact Stephanie McNew, B.S.
Phone (904) 953-0580
Email mcnew.stephanie@mayo.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers want to find out more about the side effects of Bone Marrow Aspirate Concentrate (BMAC) and what doses of BMAC are safe for people.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date October 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria - Male and Female subjects. - Subjects must be 50 years of age or older. - Subjects must have OA in a single or bilateral shoulder(s) with an inferior osteophyte measuring <7 mm. - > 1 mm joint space width in the study shoulder. - ASES score of 14.1 to 88.5 - Osteoarthritis must be primary. Subjects must have previously tried 6 months of one of the following conservative treatments: activity modification, physical therapy, and anti-inflammatory or injection therapy. - Patients can provide written informed consent after the nature of the study is fully explained. Exclusion Criteria - Patients with clinically significant abnormal hematology, serum chemistry, or urinalysis screening laboratory results. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the patient wishes. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the patient wishes. Normalization of that laboratory study will then be considered non-exclusionary. If repeat non-clinically relevant, non-life-threatening results do not normalize the patient may be further evaluated by a specialist or primary care provider to determine if lab result should be exclusionary. - Patients taking anti-inflammatory medications (prescription or over-the-counter), including herbal therapies, within 14 days of baseline visit. - Walch Type B2/C glenoid. - Patients taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within the 3 months prior to study entry. - Patients receiving injections to the treated shoulder within 3 months prior to study entry, - Patients who are pregnant or currently breast-feeding children. Females of childbearing potential must have a negative pregnancy test prior to receiving the study drug and will agree use adequate contraception (hormonal or barrier method or abstinence) from the time of screening to a period of 3 months following completion of the drug treatment cycle. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than 2 years. A urine pregnancy test will be performed prior to the administration of the study drug to confirm negative results. If the urine pregnancy test is positive, the study drug will not be administered and the result will be confirmed by a serum pregnancy test. Serum pregnancy tests will be performed at a central clinical laboratory, whereas urine pregnancy tests will be performed by qualified personnel using kit. - Patients with systemic, rheumatic or inflammatory disease of the shoulder or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the shoulder associated with juxta-articular Paget's disease, ochronosis, hemophilic arthropathy, infectious arthritis, villonodular synovitis, and synovial chondromatosis. - Patients with ongoing infectious disease, including HIV and hepatitis. - Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes. - Patients participating in a study of an experimental drug or medical device within 30 days of study entry. - Patients with hardware or implants in the affected shoulder. - Patients with previous open shoulder surgery or an arthroscopic procedure requiring structural repair with anchors and/or sutures. - Presence of large glenoid cysts - Opiate use within three months. - Patients taking Coumadin or Plavix

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Shane A. Shapiro

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Reactions Occurrence of adverse reactions to BMAC when delivered after shoulder CAM procedure 1-3 Weeks Post-Procedure
Primary Morbidity related to bone marrow aspirations from iliac crests Occurrence of adverse reactions to bone marrow aspirations from iliac crests 1-3 Weeks Post-Procedure
Secondary Change in Visual Analog Scale (VAS) Measured using the VAS questionnaire: a validated, subjective measure for pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" (0) and "worst pain" (10). Screening, pre-operatively, pre-injection and at 1 week, 6 weeks, 3 months, 6 months and 12 months following surgery
Secondary Change in American Shoulder and Elbow Surgeons Shoulder Score (ASES) Measured using the self-reported ASES questionnaire that combines pain and activities of daily living (ADL) scores for a total score out of 100, where a higher score indicates a better outcome. Screening, pre-operatively, pre-injection and at 1 week, 6 weeks, 3 months, 6 months and 12 months following surgery.
Secondary Change in Subjective Shoulder Value Subjective Shoulder Value (SSV) is a single-item self-completed measure in which patients are asked to grade their shoulder as a percentage of an entirely normal shoulder, which would score 100%. Screening, pre-operatively, pre-injection and at 1 week, 6 weeks, 3 months, 6 months and 12 months following surgery
Secondary Change in range of motion Measured in degrees Screening, pre-operatively, pre-injection and at 1 week, 6 weeks, 3 months, 6 months and 12 months following surgery
Secondary To collect and explore pre and post injection measures of cartilage status in the affected shoulder. Assessment of structural changes of the shoulder on conventional radiographs including measurement of inferior humeral osteophyte and joint space width 12 Months
See also
  Status Clinical Trial Phase
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Recruiting NCT06025331 - Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA? N/A
Recruiting NCT06153381 - Virtual Rehabilitation Assistant Via Instant Messaging Communication to Promote Adherence to Rehabilitation After Reverse Shoulder Replacement N/A
Recruiting NCT04762667 - Individual Preoperative Planning for RSA N/A
Recruiting NCT06025448 - Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability? N/A
Completed NCT03854357 - Subscapularis Strength After Total Shoulder Arthroplasty N/A
Recruiting NCT05408065 - Comparison of the Analgesic Effect of 2 Shoulder Infiltrations N/A
Recruiting NCT05048264 - Effect of Corticosteroid Injections on Blood Glucose
Recruiting NCT05395819 - Clinical Evaluation of Reverse Versus Anatomic Shoulder Arthroplasty Techniques in the Treatment of Osteoarthritis N/A
Recruiting NCT06381791 - CBD for Pain Following Orthopedic Shoulder Surgery Phase 1/Phase 2
Active, not recruiting NCT04405297 - A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells
Not yet recruiting NCT05868330 - Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties N/A
Recruiting NCT05675527 - PRP for Glenohumeral Osteoarthritis Phase 4
Recruiting NCT06319911 - AETOS Shoulder System
Withdrawn NCT03474510 - Effective Pain Management During Shoulder Replacement Surgery With EXPAREL Phase 4
Completed NCT05043493 - Effect of PRP as Therapy for Shoulder Osteoarthritis N/A
Recruiting NCT05788614 - Retroversion in Reverse Shoulder Arthroplasty N/A
Not yet recruiting NCT06435494 - Cross-sectorial Use of Patient-Reported Outcomes in Chronic Degenerative Shoulder Conditions N/A
Withdrawn NCT04285606 - Effect of Postop Rehab Methods on Outcomes Following Reverse Shoulder Arthroplasty N/A
Recruiting NCT04984291 - Zimmer Biomet Shoulder Arthroplasty PMCF N/A